Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MDxHealthLTS:0O8G 49 Market Cap is €19.00 Mil as of Jul. 22, 2026. GuruFocus rates LTS:0O8G with a GF Score™ of 49/100 and a GF Value™ of €15.73. The stock has 5 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, MDxHealth ranks worse than 67.28% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MDxHealth's share price for the quarter that ended in Mar. 2026 was €3.01983. MDxHealth's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 51.37 Mil. Therefore, MDxHealth's market cap for the quarter that ended in Mar. 2026 was €155.11 Mil.
MDxHealth's quarterly market cap
stayed the same
from Sep. 2025 (€155.11 Mil) to Dec. 2025 (€155.11 Mil) and
stayed the same
from Dec. 2025 (€155.11 Mil) to Mar. 2026 (€155.11 Mil).
MDxHealth's annual market cap
increased
from Dec. 2023 (€82.41 Mil) to Dec. 2024 (€149.47 Mil) and
increased
from Dec. 2024 (€149.47 Mil) to Dec. 2025 (€155.11 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MDxHealth's Enterprise Value for Today is €73.96 Mil.
MDxHealth (LTS:0O8G) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
MDxHealth Market Cap Related Terms
MDxHealth Market Cap Historical Data
* Premium members only.
The historical data trend for MDxHealth's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0O8G vs AWHL, BIOQ, XWEL: Market Cap Comparison
For the Diagnostics & Research subindustry, MDxHealth's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MDxHealth Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Market Cap distribution charts can be found below:
* The bar in red indicates where MDxHealth's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
MDxHealth's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDxHealth (LTS:0O8G) has a Market Cap of €19.00 Mil as of Jul. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MDxHealth and its competitors. According to the industry distribution chart, MDxHealth ranks #146 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 67.3%.
Is MDxHealth's Market Cap too high?
MDxHealth's current Market Cap is €19.00 Mil. Based on the distribution chart, MDxHealth ranks #146 out of 217 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, MDxHealth has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Market Cap compare to AWHL and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #146 out of 217 companies for Market Cap. This places MDxHealth in the lower half of its industry. The industry median Market Cap is 57.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 57.40, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MDxHealth and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 57.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MDxHealth's current Market Cap is €19.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
MDxHealth (LTS:0O8G) has a current Market Cap of €19.00 Mil. The stock's GF Value™ is €15.73, compared to a current price of €3.02 — trading 80.8% below its estimated fair value. The current Market Cap is €19.00 Mil. MDxHealth's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MDxHealth (LTS:0O8G), the current Market Cap is €19.00 Mil as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MDxHealth (LTS:0O8G) Overvalued in 2026?
Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued.
The current stock price of €3.02 is trading 80.8% below its estimated GF Value™ of €15.73.
Key valuation signals for LTS:0O8G:
Market Cap: €19.00 Mil
GF Value™: €15.73 vs. price of €3.02 (80.8% below fair value)
No single metric tells the full story. See the LTS:0O8G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
49GF Score
Get the complete analysis for LTS:0O8G
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0O8G has been successfully added to your 
